Market Closed -
Bombay S.E.
03:30:56 01/07/2024 pm IST
|
5-day change
|
1st Jan Change
|
138.1
INR
|
+0.25%
|
|
+1.43%
|
+9.04%
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
880
|
1,302
|
760
|
1,840
|
1,390
|
761.3
|
Enterprise Value (EV)
1 |
1,110
|
1,527
|
960.4
|
2,060
|
1,795
|
1,270
|
P/E ratio
|
34.1
x
|
17.3
x
|
6.98
x
|
13.4
x
|
122
x
|
-414
x
|
Yield
|
-
|
0.61%
|
1.05%
|
0.65%
|
0.29%
|
-
|
Capitalization / Revenue
|
0.78
x
|
0.83
x
|
0.45
x
|
1.01
x
|
0.69
x
|
0.41
x
|
EV / Revenue
|
0.99
x
|
0.98
x
|
0.57
x
|
1.13
x
|
0.89
x
|
0.69
x
|
EV / EBITDA
|
14.9
x
|
8.37
x
|
4.22
x
|
8.81
x
|
22.2
x
|
70.8
x
|
EV / FCF
|
-22.5
x
|
-104
x
|
93.5
x
|
-67.2
x
|
-10.3
x
|
-9.35
x
|
FCF Yield
|
-4.45%
|
-0.96%
|
1.07%
|
-1.49%
|
-9.72%
|
-10.7%
|
Price to Book
|
4.71
x
|
5.01
x
|
2.22
x
|
3.95
x
|
2.97
x
|
1.65
x
|
Nbr of stocks (in thousands)
|
8,000
|
8,000
|
8,000
|
8,000
|
8,000
|
8,000
|
Reference price
2 |
110.0
|
162.8
|
95.00
|
230.0
|
173.8
|
95.16
|
Announcement Date
|
27/08/18
|
18/08/19
|
14/08/20
|
26/08/21
|
02/09/22
|
02/09/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
1,125
|
1,563
|
1,679
|
1,821
|
2,016
|
1,839
|
EBITDA
1 |
74.56
|
182.4
|
227.4
|
234
|
80.85
|
17.92
|
EBIT
1 |
47.8
|
154.1
|
195.3
|
200.3
|
42.88
|
-26.82
|
Operating Margin
|
4.25%
|
9.86%
|
11.63%
|
11%
|
2.13%
|
-1.46%
|
Earnings before Tax (EBT)
1 |
23.64
|
123.3
|
140.9
|
172.7
|
17.39
|
0.899
|
Net income
1 |
17.14
|
75.09
|
109
|
137.1
|
11.44
|
-1.822
|
Net margin
|
1.52%
|
4.81%
|
6.49%
|
7.53%
|
0.57%
|
-0.1%
|
EPS
2 |
3.230
|
9.390
|
13.62
|
17.14
|
1.430
|
-0.2300
|
Free Cash Flow
1 |
-49.37
|
-14.71
|
10.27
|
-30.65
|
-174.6
|
-135.8
|
FCF margin
|
-4.39%
|
-0.94%
|
0.61%
|
-1.68%
|
-8.66%
|
-7.39%
|
FCF Conversion (EBITDA)
|
-
|
-
|
4.52%
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
9.43%
|
-
|
-
|
-
|
Dividend per Share
|
-
|
1.000
|
1.000
|
1.500
|
0.5000
|
-
|
Announcement Date
|
27/08/18
|
18/08/19
|
14/08/20
|
26/08/21
|
02/09/22
|
02/09/23
|
Fiscal Period: März |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
230
|
225
|
200
|
221
|
405
|
508
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
3.09
x
|
1.231
x
|
0.8816
x
|
0.9438
x
|
5.007
x
|
28.37
x
|
Free Cash Flow
1 |
-49.4
|
-14.7
|
10.3
|
-30.6
|
-175
|
-136
|
ROE (net income / shareholders' equity)
|
9.86%
|
33.6%
|
36.2%
|
34%
|
2.45%
|
-0.39%
|
ROA (Net income/ Total Assets)
|
3.31%
|
9.55%
|
10.7%
|
9.79%
|
1.71%
|
-0.88%
|
Assets
1 |
517.3
|
785.8
|
1,016
|
1,401
|
668.7
|
206.5
|
Book Value Per Share
2 |
23.40
|
32.50
|
42.80
|
58.20
|
58.50
|
57.80
|
Cash Flow per Share
2 |
0.4600
|
2.450
|
2.500
|
2.080
|
0.8100
|
1.040
|
Capex
1 |
34.6
|
72
|
71.9
|
68.5
|
172
|
135
|
Capex / Sales
|
3.08%
|
4.61%
|
4.28%
|
3.76%
|
8.51%
|
7.36%
|
Announcement Date
|
27/08/18
|
18/08/19
|
14/08/20
|
26/08/21
|
02/09/22
|
02/09/23
|
|
1st Jan change
|
Capi.
|
---|
| +9.04% | 13.22M | | +20.70% | 43.77B | | +30.16% | 22.83B | | +20.25% | 15.56B | | +18.68% | 14.34B | | +54.86% | 12.96B | | -0.05% | 6.79B | | -11.72% | 6.41B | | -8.87% | 5.73B | | +14.65% | 5.69B |
Generic Pharmaceuticals
|